• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023

    5/31/23 11:00:47 AM ET
    $ACNB
    $AKBA
    $AMBA
    $AMX
    Major Banks
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACNB alert in real time by email

    Upgrades

    For The Carlyle Group Inc (NASDAQ:CG), Raymond James upgraded the previous rating of Market Perform to Outperform. For the first quarter, Carlyle Group had an EPS of $0.63, compared to year-ago quarter EPS of $0.74. The stock has a 52-week-high of $40.73 and a 52-week-low of $24.61. At the end of the last trading period, Carlyle Group closed at $28.15.

    Piper Sandler upgraded the previous rating for Akebia Therapeutics Inc (NASDAQ:AKBA) from Neutral to Overweight. In the first quarter, Akebia Therapeutics showed an EPS of $0.14, compared to $0.35 from the year-ago quarter. The current stock performance of Akebia Therapeutics shows a 52-week-high of $1.63 and a 52-week-low of $0.24. Moreover, at the end of the last trading period, the closing price was at $0.96.

    According to BTIG, the prior rating for Q2 Holdings Inc (NYSE:QTWO) was changed from Neutral to Buy. For the first quarter, Q2 Holdings had an EPS of $0.35, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $55.26 and a 52-week-low of $18.91. At the end of the last trading period, Q2 Holdings closed at $27.65.

    For Avis Budget Group Inc (NASDAQ:CAR), Deutsche Bank upgraded the previous rating of Hold to Buy. Avis Budget Gr earned $7.72 in the first quarter, compared to $9.99 in the year-ago quarter. At the moment, the stock has a 52-week-high of $251.26 and a 52-week-low of $131.85. Avis Budget Gr closed at $163.27 at the end of the last trading period.

    According to Baird, the prior rating for Xylem Inc (NYSE:XYL) was changed from Neutral to Outperform. Xylem earned $0.72 in the first quarter, compared to $0.47 in the year-ago quarter. At the moment, the stock has a 52-week-high of $118.58 and a 52-week-low of $72.13. Xylem closed at $98.59 at the end of the last trading period.

    For Chevron Corp (NYSE:CVX), JP Morgan upgraded the previous rating of Underweight to Neutral. In the first quarter, Chevron showed an EPS of $3.55, compared to $3.36 from the year-ago quarter. The current stock performance of Chevron shows a 52-week-high of $189.66 and a 52-week-low of $132.54. Moreover, at the end of the last trading period, the closing price was at $153.12.

    See all analyst ratings upgrades.

    Downgrades

    For GreenLight Biosciences Inc (NASDAQ:GRNA), Canaccord Genuity downgraded the previous rating of Buy to Hold. GreenLight Biosciences earned $0.19 in the first quarter, compared to $0.34 in the year-ago quarter. At the moment, the stock has a 52-week-high of $8.34 and a 52-week-low of $0.18. GreenLight Biosciences closed at $0.29 at the end of the last trading period.

    According to Seaport Global, the prior rating for PDC Energy Inc (NASDAQ:PDCE) was changed from Buy to Neutral. PDC Energy earned $2.61 in the first quarter, compared to $3.66 in the year-ago quarter. The stock has a 52-week-high of $89.20 and a 52-week-low of $51.72. At the end of the last trading period, PDC Energy closed at $69.87.

    Keybanc downgraded the previous rating for Ambarella Inc (NASDAQ:AMBA) from Overweight to Sector Weight. For the first quarter, Ambarella had an EPS of $0.15, compared to year-ago quarter EPS of $0.44. The stock has a 52-week-high of $99.86 and a 52-week-low of $49.02. At the end of the last trading period, Ambarella closed at $81.96.

    See all analyst ratings downgrades.

    Initiations

    TD Cowen initiated coverage on MDxHealth SA (NASDAQ:MDXH) with an Outperform rating. The price target for MDxHealth is set to $7.00. In the first quarter, MDxHealth showed an EPS of $0.05, compared to $0.05 from the year-ago quarter.

    William Blair initiated coverage on PROCEPT BioRobotics Corp (NASDAQ:PRCT) with an Outperform rating. In the first quarter, PROCEPT BioRobotics showed an EPS of $0.63, compared to $0.39 from the year-ago quarter. At the moment, the stock has a 52-week-high of $52.40 and a 52-week-low of $25.29. PROCEPT BioRobotics closed at $31.40 at the end of the last trading period.

    With an Outperform rating, Noble Capital Markets initiated coverage on Saga Communications Inc (NASDAQ:SGA). The price target seems to have been set at $27.00 for Saga Communications. Saga Communications earned $0.15 in the first quarter, compared to $0.20 in the year-ago quarter.

    Hovde Group initiated coverage on ACNB Corp (NASDAQ:ACNB) with an Outperform rating. The price target for ACNB is set to $36.00. In the first quarter, ACNB showed an EPS of $1.06, compared to $0.76 from the year-ago quarter. The stock has a 52-week-high of $41.17 and a 52-week-low of $27.00. At the end of the last trading period, ACNB closed at $30.32.

    Northland Capital Markets initiated coverage on Near Intelligence Inc (NASDAQ:NIR) with an Outperform rating. The price target for Near Intelligence is set to $8.00. In the first quarter, Near Intelligence showed an EPS of $1.20, compared to $0.49 from the year-ago quarter. The current stock performance of Near Intelligence shows a 52-week-high of $18.65 and a 52-week-low of $1.55. Moreover, at the end of the last trading period, the closing price was at $1.80.

    For BRC Inc (NYSE:BRCC), Needham initiated coverage, by setting the current rating at Hold. BRC earned $0.08 in the first quarter, compared to $1.36 in the year-ago quarter. The current stock performance of BRC shows a 52-week-high of $11.04 and a 52-week-low of $4.79. Moreover, at the end of the last trading period, the closing price was at $5.63.

    UBS initiated coverage on argenx SE (NASDAQ:ARGX) with a Buy rating. The price target for argenx is set to $480.00. In the first quarter, argenx showed an EPS of $0.52, compared to $4.36 from the year-ago quarter. The stock has a 52-week-high of $423.99 and a 52-week-low of $304.94. At the end of the last trading period, argenx closed at $392.36.

    RBC Capital initiated coverage on Colliers International Group Inc (NASDAQ:CIGI) with an Outperform rating. The price target for Colliers Intl Gr is set to $128.00. For the first quarter, Colliers Intl Gr had an EPS of $0.86, compared to year-ago quarter EPS of $1.44. The current stock performance of Colliers Intl Gr shows a 52-week-high of $133.03 and a 52-week-low of $84.16. Moreover, at the end of the last trading period, the closing price was at $93.16.

    With a Buy rating, Goldman Sachs initiated coverage on Cedar Fair LP (NYSE:FUN). The price target seems to have been set at $50.00 for Cedar Fair. In the first quarter, Cedar Fair showed an EPS of $2.61, compared to $1.56 from the year-ago quarter. The current stock performance of Cedar Fair shows a 52-week-high of $49.36 and a 52-week-low of $37.92. Moreover, at the end of the last trading period, the closing price was at $44.17.

    Goldman Sachs initiated coverage on SeaWorld Entertainment Inc (NYSE:SEAS) with a Buy rating. The price target for SeaWorld Entertainment is set to $75.00. SeaWorld Entertainment earned $0.26 in the first quarter, compared to $0.12 in the year-ago quarter. The stock has a 52-week-high of $68.19 and a 52-week-low of $40.02. At the end of the last trading period, SeaWorld Entertainment closed at $56.00.

    Needham initiated coverage on Sovos Brands Inc (NASDAQ:SOVO) with a Buy rating. The price target for Sovos Brands is set to $22.50. In the first quarter, Sovos Brands showed an EPS of $0.18, compared to $0.14 from the year-ago quarter. The stock has a 52-week-high of $20.58 and a 52-week-low of $12.50. At the end of the last trading period, Sovos Brands closed at $18.48.

    With a Sell rating, Goldman Sachs initiated coverage on Six Flags Entertainment Corp (NYSE:SIX). The price target seems to have been set at $26.00 for Six Flags Entertainment. Six Flags Entertainment earned $0.84 in the first quarter, compared to $0.76 in the year-ago quarter. The current stock performance of Six Flags Entertainment shows a 52-week-high of $31.29 and a 52-week-low of $16.83. Moreover, at the end of the last trading period, the closing price was at $25.48.

    With a Buy rating, Goldman Sachs initiated coverage on Telefonica Brasil SA (NYSE:VIV). The price target seems to have been set at $10.00 for Telefonica Brasil. For the fourth quarter, Telefonica Brasil had an EPS of $0.13, compared to year-ago quarter EPS of $0.28. The stock has a 52-week-high of $11.03 and a 52-week-low of $6.49. At the end of the last trading period, Telefonica Brasil closed at $8.12.

    William Blair initiated coverage on Qualys Inc (NASDAQ:QLYS) with an Outperform rating. For the first quarter, Qualys had an EPS of $1.09, compared to year-ago quarter EPS of $0.89. The stock has a 52-week-high of $162.36 and a 52-week-low of $101.10. At the end of the last trading period, Qualys closed at $122.91.

    With an Outperform rating, RBC Capital initiated coverage on Nevro Corp (NYSE:NVRO). The price target seems to have been set at $40.00 for Nevro. In the first quarter, Nevro showed an EPS of $0.98, compared to $0.98 from the year-ago quarter. The current stock performance of Nevro shows a 52-week-high of $53.22 and a 52-week-low of $25.82. Moreover, at the end of the last trading period, the closing price was at $26.04.

    With a Neutral rating, Goldman Sachs initiated coverage on TIM SA (NYSE:TIMB). The price target seems to have been set at $15.00 for TIM. At the moment, the stock has a 52-week-high of $15.27 and a 52-week-low of $10.20. TIM closed at $14.27 at the end of the last trading period.

    Goldman Sachs initiated coverage on America Movil SAB de CV (NYSE:AMX) with a Neutral rating. The price target for America Movil is set to $24.00. In the first quarter, America Movil showed an EPS of $0.51, compared to $0.47 from the year-ago quarter. The stock has a 52-week-high of $23.07 and a 52-week-low of $15.68. At the end of the last trading period, America Movil closed at $21.99.

    Goldman Sachs initiated coverage on Liberty Latin America Ltd (NASDAQ:LILA) with a Buy rating. The price target for Liberty Latin America is set to $10.00. For the first quarter, Liberty Latin America had an EPS of $0.23, compared to year-ago quarter EPS of $0.36. The current stock performance of Liberty Latin America shows a 52-week-high of $10.01 and a 52-week-low of $5.90. Moreover, at the end of the last trading period, the closing price was at $7.29.

    With a Buy rating, Goldman Sachs initiated coverage on Grupo Televisa SAB (NYSE:TV). The price target seems to have been set at $6.10 for Grupo Televisa. For the first quarter, Grupo Televisa had an EPS of $0.07, compared to year-ago quarter EPS of $0.18. The current stock performance of Grupo Televisa shows a 52-week-high of $10.39 and a 52-week-low of $4.38. Moreover, at the end of the last trading period, the closing price was at $4.76.

    With a Buy rating, Roth MKM initiated coverage on ASLAN Pharmaceuticals Ltd (NASDAQ:ASLN). The price target seems to have been set at $15.00 for ASLAN Pharma. For the first quarter, ASLAN Pharma had an EPS of $1.29, compared to year-ago quarter EPS of $0.95. The current stock performance of ASLAN Pharma shows a 52-week-high of $4.93 and a 52-week-low of $1.70. Moreover, at the end of the last trading period, the closing price was at $3.72.

    Roth MKM initiated coverage on Inventiva SA (NASDAQ:IVA) with a Buy rating. The price target for Inventiva is set to $11.00. None

    With a Buy rating, Roth MKM initiated coverage on Terns Pharmaceuticals Inc (NASDAQ:TERN). The price target seems to have been set at $23.00 for Terns Pharma. In the first quarter, Terns Pharma showed an EPS of $0.31, compared to $0.55 from the year-ago quarter. The current stock performance of Terns Pharma shows a 52-week-high of $14.04 and a 52-week-low of $1.53. Moreover, at the end of the last trading period, the closing price was at $10.56.

    With a Buy rating, Roth MKM initiated coverage on Unity Biotechnology Inc (NASDAQ:UBX). The price target seems to have been set at $10.00 for Unity Biotechnology. For the first quarter, Unity Biotechnology had an EPS of $0.76, compared to year-ago quarter EPS of $2.80. The current stock performance of Unity Biotechnology shows a 52-week-high of $18.50 and a 52-week-low of $1.46. Moreover, at the end of the last trading period, the closing price was at $2.93.

    With a Neutral rating, DA Davidson initiated coverage on MasterCraft Boat Holdings Inc (NASDAQ:MCFT). The price target seems to have been set at $29.00 for MasterCraft Boat Hldgs. For the third quarter, MasterCraft Boat Hldgs had an EPS of $1.36, compared to year-ago quarter EPS of $1.36. The current stock performance of MasterCraft Boat Hldgs shows a 52-week-high of $35.29 and a 52-week-low of $18.49. Moreover, at the end of the last trading period, the closing price was at $26.71.

    With a Buy rating, Mizuho initiated coverage on NICE Ltd (NASDAQ:NICE). The price target seems to have been set at $244.00 for NICE. For the first quarter, NICE had an EPS of $2.03, compared to year-ago quarter EPS of $1.80. The current stock performance of NICE shows a 52-week-high of $235.05 and a 52-week-low of $164.86. Moreover, at the end of the last trading period, the closing price was at $196.57.

    Mizuho initiated coverage on Five9 Inc (NASDAQ:FIVN) with a Buy rating. The price target for Five9 is set to $100.00. For the first quarter, Five9 had an EPS of $0.41, compared to year-ago quarter EPS of $0.22. At the moment, the stock has a 52-week-high of $120.29 and a 52-week-low of $46.63. Five9 closed at $60.88 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $ACNB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACNB
    $AKBA
    $AMBA
    $AMX

    CompanyDatePrice TargetRatingAnalyst
    Terns Pharmaceuticals Inc.
    $TERN
    2/9/2026$58.00Outperform
    Leerink Partners
    Six Flags Entertainment Corporation
    $FUN
    2/5/2026$20.00Buy → Neutral
    Citigroup
    Colliers International Group Inc. Subordinate Voting Shares
    $CIGI
    2/4/2026$200.00Outperform → Strong Buy
    Raymond James
    Q2 Holdings Inc.
    $QTWO
    2/3/2026$82.00Neutral → Buy
    DA Davidson
    Chevron Corporation
    $CVX
    2/2/2026$160.00 → $168.00Hold
    TD Cowen
    Chevron Corporation
    $CVX
    2/2/2026$180.00Buy → Hold
    HSBC Securities
    Inventiva S.A.
    $IVA
    1/28/2026$18.00Overweight
    Barclays
    Xylem Inc.
    $XYL
    1/26/2026Outperform
    William Blair
    More analyst ratings

    $ACNB
    $AKBA
    $AMBA
    $AMX
    SEC Filings

    View All

    SEC Form 10-K filed by Q2 Holdings Inc.

    10-K - Q2 Holdings, Inc. (0001410384) (Filer)

    2/11/26 5:02:54 PM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form F-3/A filed by MDxHealth SA

    F-3/A - MDxHealth SA (0001872529) (Filer)

    2/11/26 4:40:53 PM ET
    $MDXH
    Medical Specialities
    Health Care

    SEC Form 6-K filed by MDxHealth SA

    6-K - MDxHealth SA (0001872529) (Filer)

    2/11/26 4:29:53 PM ET
    $MDXH
    Medical Specialities
    Health Care

    $ACNB
    $AKBA
    $AMBA
    $AMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Newell Donna M

    5 - ACNB CORP (0000715579) (Issuer)

    2/10/26 3:30:44 PM ET
    $ACNB
    Major Banks
    Finance

    Ramakrishna Sudhakar increased direct ownership by 0.50% to 21,336 units (SEC Form 5)

    5 - Five9, Inc. (0001288847) (Issuer)

    2/9/26 6:14:55 PM ET
    $FIVN
    EDP Services
    Technology

    SEC Form 3 filed by new insider Mathradas Amit

    3 - Five9, Inc. (0001288847) (Issuer)

    2/9/26 4:20:16 PM ET
    $FIVN
    EDP Services
    Technology

    $ACNB
    $AKBA
    $AMBA
    $AMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Terns Pharmaceuticals with a new price target

    Leerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00

    2/9/26 6:54:14 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Six Flags Entertainment downgraded by Citigroup with a new price target

    Citigroup downgraded Six Flags Entertainment from Buy to Neutral and set a new price target of $20.00

    2/5/26 6:59:51 AM ET
    $FUN
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Colliers upgraded by Raymond James with a new price target

    Raymond James upgraded Colliers from Outperform to Strong Buy and set a new price target of $200.00

    2/4/26 8:06:33 AM ET
    $CIGI
    Real Estate
    Finance

    $ACNB
    $AKBA
    $AMBA
    $AMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q2 Holdings, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results

    Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for financial services, today announced results for its fourth quarter and full year ending December 31, 2025. GAAP Results for the Fourth Quarter and Full-Year 2025 Revenue for the fourth quarter of $208.2 million, up 14 percent year-over-year and up 3 percent from the third quarter of 2025. Full-year 2025 revenue of $794.8 million, up 14 percent year-over-year. GAAP gross margin for the fourth quarter of 55.4 percent, up from 52.6 percent for the prior-year quarter and up from 54.0 percent for the third quarter of 2025. GAAP gross margin for full-year 2025 of 54.1 percent, up from 50.9 percent fo

    2/11/26 4:15:00 PM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    Chevron Enters Libya With New Block Award as Part of Broader Exploration Growth Strategy

    Chevron Corporation (NYSE:CVX) by its subsidiary Chevron Business Development EMEA Ltd., has entered Libya after it was designated as a winning bidder in the 2025 Libyan Bid Round. This follows the signing of a Memorandum of Understanding (MoU) with the country's National Oil Corporation (NOC). Chevron was designated as the winning bidder for Contract Area 106 located in the Sirte Basin on February 11, 2026 in Libya's 2025 Bidding Round. On January 24, 2026 Chevron separately signed an MoU with NOC in Tripoli to evaluate the development and exploration potential onshore Libya. "Chevron is excited to enter Libya with the award of onshore Contract Area 106, which underscores our focus on

    2/11/26 9:15:00 AM ET
    $CVX
    Integrated oil Companies
    Energy

    Five9 Honors Global Partner Award Winners, Recognizing Excellence in CX Innovation, Performance, and Customer Impact

    Awards celebrate partners who delivered measurable results and advanced AI-elevated customer experiences worldwide Five9 (NASDAQ:FIVN), provider of the Intelligent CX Platform, today announced the winners of its 2025 Global Partner Awards. The awards recognize partners who delivered exceptional performance, innovation, and measurable customer outcomes across the Five9 ecosystem in 2025. This year's winners reflect the breadth of the Five9 ecosystem, spanning technology alliances, systems integrators, and CX innovators. Together, they demonstrate how partners are delivering scalable, AI-elevated customer experiences across a diverse set of industries and regions. "Our partners drove re

    2/10/26 4:05:00 PM ET
    $FIVN
    EDP Services
    Technology

    $ACNB
    $AKBA
    $AMBA
    $AMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Coliseum Capital Management, Llc bought $2,649,367 worth of shares (134,807 units at $19.65) (SEC Form 4)

    4 - MasterCraft Boat Holdings, Inc. (0001638290) (Issuer)

    12/22/25 7:54:39 PM ET
    $MCFT
    Marine Transportation
    Industrials

    Director Elsner Frank Iii was granted 150 units of ACNB Corporation Common and bought $250 worth of ACNB Corporation Common (5 units at $52.65), increasing direct ownership by 0.61% to 28,174 units (SEC Form 4)

    4 - ACNB CORP (0000715579) (Issuer)

    12/17/25 1:23:23 PM ET
    $ACNB
    Major Banks
    Finance

    Director Kelley Scott L bought $15,840 worth of ACNB Corporation Common (396 units at $40.00), increasing direct ownership by 1% to 27,425 units (SEC Form 4)

    4 - ACNB CORP (0000715579) (Issuer)

    11/21/25 11:43:46 AM ET
    $ACNB
    Major Banks
    Finance

    $ACNB
    $AKBA
    $AMBA
    $AMX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACNB
    $AKBA
    $AMBA
    $AMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nevro Corp.

    SC 13G - NEVRO CORP (0001444380) (Subject)

    12/4/24 4:27:18 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Five9 Inc.

    SC 13G - Five9, Inc. (0001288847) (Subject)

    11/21/24 6:17:26 AM ET
    $FIVN
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)

    11/15/24 5:22:29 PM ET
    $CG
    Investment Managers
    Finance

    $ACNB
    $AKBA
    $AMBA
    $AMX
    Financials

    Live finance-specific insights

    View All

    Q2 Holdings, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results

    Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for financial services, today announced results for its fourth quarter and full year ending December 31, 2025. GAAP Results for the Fourth Quarter and Full-Year 2025 Revenue for the fourth quarter of $208.2 million, up 14 percent year-over-year and up 3 percent from the third quarter of 2025. Full-year 2025 revenue of $794.8 million, up 14 percent year-over-year. GAAP gross margin for the fourth quarter of 55.4 percent, up from 52.6 percent for the prior-year quarter and up from 54.0 percent for the third quarter of 2025. GAAP gross margin for full-year 2025 of 54.1 percent, up from 50.9 percent fo

    2/11/26 4:15:00 PM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    Xylem Reports Fourth Quarter and Full Year 2025 Results

    Fourth-Quarter Highlights Orders of $2.4 billion, up 9% on a reported basis and 7% organically Revenue of $2.4 billion, up 6% on a reported basis and 4% organically Earnings per share of $1.37, up 2%; $1.42 on an adjusted basis, up 20% Full-Year Highlights Revenue of $9.0 billion, up 6% on a reported basis and 5% organically Earnings per share of $3.92, up 7%; $5.08 on an adjusted basis, up 19% Initiating 2026 full-year revenue guidance of $9.1 to $9.2 billion, up 2% to 4% organically, and adjusted earnings per share of $5.35 to $5.60 Xylem Inc. (NYSE:XYL), a leading global water solutions company dedicated to solving the world's most challenging water issues, today

    2/10/26 6:55:00 AM ET
    $XYL
    Fluid Controls
    Industrials

    Ambarella Announces Fourth Quarter and Fiscal Year 2026 Earnings Conference Call to be Held February 26, 2026

    SANTA CLARA, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ:AMBA), an edge AI semiconductor company, today announced it will hold its fourth quarter and fiscal year 2026 earnings conference call on Thursday, February 26, 2026 at 1:30 p.m. (Pacific Time). The company will issue its earnings release after the market closes that same day. Those interested in asking a question on the call are required to register online in advance. Upon completing the first step of the online registration process, please note a registration verification code will be emailed to you, and this code must be entered to complete the online registration process. Once registered and verified, the d

    2/5/26 8:00:00 PM ET
    $AMBA
    Semiconductors
    Technology

    $ACNB
    $AKBA
    $AMBA
    $AMX
    Leadership Updates

    Live Leadership Updates

    View All

    Carlyle to Host 2026 Shareholder Update

    WASHINGTON and NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) announced today that it will host a Shareholder Update on Thursday, February 26, 2026. The Shareholder Update will include a series of presentations by the company's senior leadership team and will review Carlyle's growth outlook and financial objectives. Presentations will begin at 8:30 a.m. EST, followed by a Q&A session. Presentation materials and a live webcast will be posted on the day of the event and can be accessed on the Events & Presentations section of ir.carlyle.com. For those unable to join the live webcast, a replay will be available on the website following the event. Any

    2/2/26 8:01:00 AM ET
    $CG
    Investment Managers
    Finance

    Acentra Health Appoints Balajee Sethuraman as Executive Vice President and Chief Business Services Officer

    MCLEAN, Va., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions company dedicated to accelerating better health outcomes for government and commercial clients and the populations they serve, today announced the appointment of Balajee Sethuraman as Executive Vice President and Chief Business Services Officer (CBSO), where he will lead the company's business services and delivery operations. This strategic addition to Acentra Health's executive leadership team supports its ongoing efforts to streamline and strengthen enterprise-wide delivery through a unified operating model. "Balajee is a transformative leader with exceptional experience scaling global team

    1/27/26 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    Colliers appoints Ludovic Delaisse as CEO of Colliers France

    PARIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Colliers has appointed Ludovic Delaisse as Chief Executive Officer (CEO) of Colliers France, effective today. This marks the next step in a planned leadership transition designed to strengthen Colliers' position in France and across EMEA. Delaisse succeeds Antoine Derville, who will continue as Chairman of Colliers France. Since 2021, Delaisse has served as Managing Director, overseeing all transactional and advisory service lines. He brings more than 30 years of industry experience, including senior roles at JLL and Cushman & Wakefield. Davoud Amel-Azizpour, CEO of Colliers EMEA, said: "Ludovic's appointment reflects our commitment to developing

    1/23/26 2:30:00 AM ET
    $CIGI
    Real Estate
    Finance